SMSarah A. Martin

Sarah A. Martin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sarah A. Martin has a total of 9 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Esophageal parakeratosis: case report and brief review of literature

    by Yan Shan Tan, Isaac Jia Ying Tay, Sarah Martin

    Introduction and importance: Esophageal parakeratosis is a rare benign entity that remains poorly understood, with only a few cases described in the literature. Although no definitive malignant potential has been established, the association remains uncertain. We present the first reported case of esophageal parakeratosis in Australia and review the current literature to further elucidate its clinical significance and underlying mechanisms. Case presentation: A 77-year-old man was admitted with epigastric pain. Imaging and pathology were unremarkable. He was treated for presumed gastritis and discharged. Subsequent elective gastroscopy revealed circumferential esophagitis (20–40 cm) with superficial mucosal sloughing and a 5 mm antral polyp. Histology showed esophageal parakeratosis with mild chronic inflammation, but no dysplasia or malignancy, and no evidence of fungal infiltration. The patient was treated with proton-pump inhibitors and sucralfate, which he reported had improved his symptoms. Clinical discussion: Recognition of this condition is important for endoscopists due to its potential diagnostic implications and overlap with other esophageal pathologies. Endoscopic appearances are typically described as a whitish plaque or strip that may be peeled off. It is reported to be associated with various vitamin and mineral deficiencies. It has been previously linked esophageal and head and neck malignancies, although the evidence is unclear. There are no established guidelines for management; it has to be tailored to individual patients. Conclusion: Whilst the management of esophageal parakeratosis remains a clinical dilemma, prompt recognition is important.

  • Single-dose Preoperative Glucocorticoids in Major Gastrointestinal Surgery

    by Rathin Gosavi, Baxter Smith, Kavindu Hathurusinghe, Anjana Ravi, Sarah A. Martin, Walston Reginald Martis, Vignesh Narasimhan, Geraldine Oo

    Objective: To evaluate the clinical efficacy and safety of single-dose preoperative systemic glucocorticoids in adults undergoing major gastrointestinal surgery. Summary of Background Data: Major gastrointestinal surgery induces a systemic inflammatory response that contributes to postoperative morbidity and delayed recovery. Single-dose glucocorticoids attenuate inflammation, but uncertainty remains regarding clinical benefit, safety, and optimal dosing. Methods: A PRISMA-compliant systematic review and meta-analysis of randomized controlled trials was performed and registered with PROSPERO. Trials comparing a single preoperative systemic glucocorticoid with placebo or no steroid in adult major gastrointestinal surgery were included. Primary outcomes were total postoperative complications and infectious complications. Secondary outcomes included length of stay, anastomotic leak, postoperative day 1 inflammatory markers, and mortality. Random-effects models were used. Dose-stratified analyses were prespecified and exploratory. Results: Eighteen randomized trials, including 3667 patients were analyzed. Preoperative glucocorticoids reduced total postoperative complications (OR 0.69, 95% CI: 0.54–0.89; I²=12%) and infectious complications (OR 0.62, 95% CI: 0.45–0.88; I²=55%). Length of stay was reduced by 1.09 days (95% CI: −1.68 to −0.50). Postoperative day 1 IL-6 was lower with glucocorticoids, while CRP showed no consistent difference. Anastomotic leak and mortality were not increased. Exploratory analyses suggested greater benefit with higher-dose regimens. Conclusions: Single-dose preoperative systemic glucocorticoids reduce postoperative morbidity, infections, and length of stay after major gastrointestinal surgery, without evidence of increased surgical harm in included trial populations.